drugset / Trial / NCT00013663
Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
Phase 2
Completed
92 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
New York Presbyterian Hospital · collab
Double-blindTreatment
Summary
The purpose of this study is to determine if HIV-specific canarypox vaccine and/or interleukin-2 (IL-2) will control viral load (amount of HIV in the blood) after HIV treatment is withdrawn for a certain time period.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALVAC(2)120(B,MN)GNP | Vaccine | — | Other |
| Subject | aldesleukin | Protein / enzyme biologic | — | Other |